1、公司 2024 年度权益分派方案为：以截至 2024 年 12 月 31 日公司股份总 数 882,257,450 股为基数，向全体股东按每 10 股派发现金股利人民币 7.00 元（含 税），合计派发现金股利 617,580,215.00 元，剩余未分配利润结转以后年度分配， 不送红股，不以资本公积金转增股本。 2、公司股本总额自分配方案披露至实施期间未发生变化；若公司股本总额 在权益分派实施前发生变化，公司将按照分配比例不变的原则对分配总额进行调 整。 3、本次实施的分配方案与公司 2024 年年度股东大会审议通过的分配方案及 其调整原则一致。 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 证券代码：002690 证券简称：美亚光电 公告编号：2025-014 合肥美亚光电技术股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥美亚光电技术股份有限公司（以下简称"公司"）2024 年度利润分配方 案已获 2025 年 4 月 22 日召开的 2024 年年度股东大会审议通过，现将权益分派 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥392,340,157.04, representing an increase of 18.39% compared to ¥331,400,004.80 in the same period last year[5] - Net profit attributable to shareholders was ¥108,455,126.71, up 7.49% from ¥100,900,473.07 year-on-year[5] - Total operating revenue for the current period reached ¥392,340,157.04, an increase of 18.4% compared to ¥331,400,004.80 in the previous period[20] - Net profit for the current period was ¥108,455,126.71, representing a growth of 7.5% from ¥100,900,473.07 in the previous period[21] - The total comprehensive income for the current period was ¥115,208,159.49, compared to ¥77,751,141.83 in the prior period, an increase of 48.2%[21] Cash Flow - The net cash flow from operating activities improved significantly to ¥57,178,541.55, a 201.09% increase from a negative cash flow of -¥56,559,795.05 in the previous year[5] - The company reported a significant increase in cash received from operating activities, totaling ¥45,637,105.47, which is 168.50% higher than ¥16,997,217.60 in the previous year[10] - Operating cash flow generated a net amount of ¥57,178,541.55, a significant improvement from a negative ¥56,559,795.05 in the previous period[24] - Cash inflow from operating activities totaled ¥539,111,932.11, compared to ¥416,779,029.20 in the prior year, reflecting a year-over-year increase of approximately 29.3%[24] - Cash outflow from operating activities was ¥481,933,390.56, slightly up from ¥473,338,824.25, indicating a marginal increase of about 1.2%[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥3,415,577,397.86, reflecting a 2.33% increase from ¥3,337,783,990.61 at the end of the previous year[5] - The total liabilities decreased to ¥481,199,522.76 from ¥549,779,197.80, a reduction of 12.4%[19] - The total equity attributable to shareholders rose to ¥2,934,377,875.10, up from ¥2,788,004,792.81, an increase of 5.2%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,768[14] - The largest shareholder, Tian Ming, holds 60.92% of shares, totaling 537,462,900 shares[14] - The top 10 shareholders hold a significant portion of shares, with the top three accounting for over 67%[14] Expenses - The company's sales expenses increased by 33.81% to ¥44,719,236.90, primarily due to higher sales revenue[11] - Research and development expenses increased to ¥29,037,017.55, compared to ¥24,970,715.89 in the previous period, marking an increase of 16.4%[20] Cash and Cash Equivalents - Cash and cash equivalents decreased to ¥1,474,464,320.36 from ¥1,560,367,800.56[18] - The net increase in cash and cash equivalents was ¥36,818,839.24, down from ¥144,322,343.70 in the previous period[25] - The ending balance of cash and cash equivalents stood at ¥1,445,303,209.01, compared to ¥1,530,116,625.88 at the end of the previous year[25] Other Financial Metrics - The company's basic earnings per share rose to ¥0.1230, marking a 7.33% increase from ¥0.1146 in the same quarter last year[5] - The weighted average return on equity increased to 3.81%, up from 3.60% year-on-year[5] - Other comprehensive income after tax was ¥6,753,032.78, a significant recovery from a loss of ¥23,149,331.24 in the previous period[21] - The company reported a financial income of ¥10,586,561.44, down from ¥13,480,580.77, a decrease of 21.5%[20] Investment Activities - Investment activities resulted in a net cash outflow of ¥21,411,581.45, contrasting with a net inflow of ¥190,257,241.15 in the previous year[24] - Cash inflow from investment activities was ¥301,647,684.54, up from ¥201,329,312.88, marking a year-over-year increase of approximately 49.8%[24] - Cash outflow from investment activities surged to ¥323,059,265.99 from ¥11,072,071.73, indicating a significant increase in investment spending[24] Audit Status - The first quarter report was not audited, indicating that the financial figures are preliminary and subject to change[26]

证券代码：002690 证券简称：美亚光电 公告编号：2025-011 合肥美亚光电技术股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 合肥美亚光电技术股份有限公司（以下简称"公司"）董事会于2025年03月 28日在《证券时报》、巨潮资讯网（http://www.cninfo.com.cn）上刊登了《关 于召开2024年年度股东大会的通知》。 （2）现场会议召开地点：合肥市高新技术产业开发区望江西路668号公司会 议室 （3）股权登记日：2025年4月15日 （4）会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式 召开。 1、会议召开情况 （1）会议召开时间 现场会议时间：2025年4月22日下午14:30 网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为2025年4月22日上 午9:15—9:25、9:30－11:30和下午13:00－15:00。 通过 ...

证券代码：002690 证券简称：美亚光电 公告编号：2025-012 合肥美亚光电技术股份有限公司 关于回购注销部分已授予限制性股票减资 暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 合肥美亚光电技术股份有限公司（以下简称"公司"）第五届董事会第十 二次会议、第五届监事会第十一次会议以及2024年年度股东大会，分别审议通 过了《关于回购注销部分限制性股票的议案》。 鉴于首次及预留授予的激励对象中共有6名激励对象已离职，其中，首次授 予部分激励对象离职人数2名，预留授予部分激励对象离职人数6名（本次首次 授予及预留授予离职激励对象部分重合），上述离职人员不再具备激励对象资 格，根据《公司2021年限制性股票激励计划（草案）》及相关法律、法规的规 定，公司决定对其已获授但尚未解除限售的22,400股限制性股票进行回购注 销。 本次回购注销已授予但尚未解除限售的制性股票总计22,400股，占公司总 股本882,257,450股的比例为0.0025%。本次回购注销完成后，公司总股本将由 882,257,450股减少至882,235,050股。 公司 ...

法律意见书 安徽天禾律师事务所 关于合肥美亚光电技术股份有限公司 2024 年年度股东大会的法律意见书 - 1 - 法律意见书 年 4 月 22 日上午 9:15～9:25、9:30～11:30 和下午 13:00～15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 4 月 22 日上午 9:15 至下午 15:00。本次股东大会召开的实际时间、地点、方式、会议审议的议案与会议通知 内容一致。 天律意 2025 第 00805 号 致：合肥美亚光电技术股份有限公司 根据《中华人民共和国公司法》(下称"《公司法》")、《中华人民共和 国证券法》（下称"《证券法》"）、《上市公司股东会规则》和《合肥美亚 光电技术股份有限公司章程》（下称"《公司章程》"）的有关规定，安徽天 禾律师事务所接受合肥美亚光电技术股份有限公司（下称"公司"）的委托， 指派本所李军、陈策律师出席公司 2024 年年度股东大会（下称"本次股东大 会"），并对本次股东大会相关事项进行见证，出具法律意见。 本所同意将本法律意见书作为本次股东大会的公告文件，随公司其他文件一 并报送有关主管部门审查并予以公告。 本所根据《证 ...

合肥美亚光电技术股份有限公司 章程 二〇二五年四月 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 第一章 总则 第一条 为维护合肥美亚光电技术股份有限公司（以下简称"公司"）、股东 和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和 其他有关规定，制订本章程。 第二条 ...

Group 1: Business Performance and Growth - The company's color sorting machine business is experiencing steady growth due to the stable increase in domestic grain production and diverse market demands, despite the market being relatively mature [2][4] - The company has increased investments in R&D and marketing services, enhancing product competitiveness and service capabilities [2][4] - The company reported a good operating condition in Q1 2025, with all business segments developing steadily [5] Group 2: Market Challenges and Strategies - The impact of increased U.S. tariffs on exports is minimal, as sales to the U.S. account for a small proportion of total exports; the company will monitor market changes and adjust strategies accordingly [3] - The oral health business faced significant challenges in 2024, with a substantial decline due to economic conditions and intensified competition, but the company remains optimistic about future growth in the domestic oral health market [4] Group 3: Inventory and Cost Management - The company has reduced the proportion of business through distributors, maintaining low inventory levels without any backlog [6] - The company holds a significant advantage in cost control due to scale effects, efficient production capabilities of smart factories, and self-manufacturing of key components [7] Group 4: Product Development and Market Potential - The mobile CT system is designed for bedside imaging and has versatile applications in various medical scenarios, showing strong market potential [8] - The company has consistently returned value to investors through cash dividends, totaling over 4 billion yuan since its listing, and plans to maintain this policy if no major capital expenditures arise [8]

Group 1: Financial Performance - The company's overall revenue decreased by 4.73% in 2024, and net profit attributable to shareholders fell by 12.84% [2] - The company aims to focus on its core business and increase investments in R&D and marketing to reverse the performance decline in 2025 [2] - The X-ray industrial inspection machine accounted for 6.46% of main revenue with a high gross margin of 60.08%, indicating strong profitability [14] Group 2: Market Strategies - The company achieved nearly 10% growth in the domestic market for color sorting machines despite market maturity, while export revenue increased by 13% [3] - The company plans to enhance product innovation and marketing efforts to ensure stable high-quality development [3] - The company is actively exploring the application of AI models to empower its products [5] Group 3: Industry Outlook and Investments - The company is optimistic about the future of the domestic dental industry, expecting growth due to stable economic development and an aging population [5] - The company is expanding its existing medical product sales and exploring new directions in medical imaging [4] - The company has no current plans for mergers or acquisitions but is focused on strengthening its core business [15] Group 4: Operational Insights - The company has successfully completed the localization of major product components and maintains a stable supply chain [16] - The operating cash flow per share increased by 29.97% year-on-year in 2024, reflecting improved cash flow management [18] - The "Meiya Meiya" dental health digital cloud platform has rapidly developed, serving over 10,000 customers since its launch [17]

Summary of Meyer Optoelectronic Tech (002690.SZ) Conference Call Company Overview - **Company**: Meyer Optoelectronic Technology - **Ticker**: 002690.SZ - **Industry**: Dental imaging and optoelectronic detection equipment Key Points Industry and Market Dynamics - **Demand Recovery**: Management indicated signs of improvement in dental CBCT demand since Q4 2024, with a 6.8% YoY growth in the number of dental clinics in China in 2024, compared to 3.7% in 2023 [2][11] - **Competitive Landscape**: The dental clinic industry is highly competitive, with a significant number of closures in 2023/24, suggesting that demand for dental CBCT may come from price-sensitive areas [2][12] - **Price Competition**: Ongoing price competition is expected to persist in a lukewarm demand environment, particularly after the implementation of bulk purchasing policies for dental implants [1][27] Financial Performance and Forecasts - **Earnings Forecasts**: Earnings forecasts for 2025 and 2026 have been trimmed by 7% and 8% respectively, reflecting a challenging outlook for dental CBCT revenue [1][9] - **Revenue Growth**: Actual revenue and earnings growth have historically only met or exceeded financial budget targets one or two times from 2015 to 2024 [2][19] - **2025 Projections**: Forecasted revenue and earnings growth for 2025E is 9% and 8% YoY, respectively, with expectations of continued sales decline and gross profit margin (GPM) contraction [2][27] Valuation and Target Price - **Target Price Adjustment**: The target price has been raised by approximately 17% to Rmb16.6, based on a new P/E ratio of ~21 for 2025E, reflecting positive YoY earnings growth expectations [3][28] - **Market Capitalization**: The current market cap is Rmb15,131 million (approximately US$2,083 million) [5][8] Financial Metrics - **Earnings Summary**: - 2023A: Net Profit Rmb745 million, Diluted EPS Rmb0.846, P/E 20.3x - 2024A: Net Profit Rmb649 million, Diluted EPS Rmb0.737, P/E 23.3x - 2025E: Net Profit Rmb702 million, Diluted EPS Rmb0.795, P/E 21.6x - 2026E: Net Profit Rmb787 million, Diluted EPS Rmb0.892, P/E 19.2x - 2027E: Net Profit Rmb893 million, Diluted EPS Rmb1.011, P/E 17.0x [4][8] Risks and Concerns - **Upside Risks**: Potential for better-than-expected GPM and faster revenue growth due to demand recovery [29] - **Downside Risks**: Risks include worse-than-expected GPM, slower revenue growth, and potential dividend payout cuts due to cash flow pressures [29] Conclusion - **Investment Rating**: The company maintains a Neutral rating due to concerns over weaker dental CBCT demand and intensifying price competition in the industry [1][27]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's core business remains stable, with expectations for recovery in the medical sector [2][4] - In 2024, the company reported revenue of 2.31 billion yuan, a year-over-year decrease of 4.7%, and a net profit attributable to shareholders of 650 million yuan, down 12.8% year-over-year [1][4] Performance Summary - Revenue in Q4 2024 was 730 million yuan, a year-over-year decrease of 4.6%, while net profit attributable to shareholders was 200 million yuan, up 9.6% year-over-year [1] - The company’s color sorting machine business generated revenue of 1.62 billion yuan in 2024, reflecting a year-over-year increase of 9.9% [2] - The medical equipment segment, particularly the CBCT, saw revenue decline to 500 million yuan, down 33.4% year-over-year [3] Growth Potential - The color sorting machine market is expected to continue stable growth, with new product launches enhancing competitiveness [2] - The recovery in the medical sector is anticipated to be driven by economic recovery and increased demand for dental implants and orthodontics [3] Profitability Analysis - The company's gross margin for 2024 was 50.4%, a decrease of 1.1 percentage points year-over-year, while the net profit margin was 28.1%, down 2.6 percentage points [4] - Operating cash flow for 2024 was 880 million yuan, a year-over-year increase of 30.0% [4] Earnings Forecast and Valuation - Earnings per share (EPS) are projected to be 0.80 yuan in 2025, 0.88 yuan in 2026, and 0.98 yuan in 2027 [4] - The current closing price corresponds to a price-to-earnings (P/E) ratio of 21.8 times for 2025 [4]